Caplan's 1991 paper formally names mesenchymal stem cells (MSCs) and answers the question: what cell gives rise to skeletal tissues, and what controls its fate? It synthesizes over 20 years of lineage work to show that bone and cartilage arise from a common progenitor through discrete, irreversible steps governed by genomic programming and local environmental cues. The paper then proposes that MSCs can be harvested, expanded ex vivo, and redeployed autologously — the conceptual origin of modern cell-based orthopedic therapies.
The vascular rule Caplan described explains observations residents encounter daily: periosteal stripping impairs fracture healing, avascular cartilage cannot spontaneously remodel into bone, and scaffold design for cartilage repair must exclude vasculature while bone scaffolds must invite it.
When you consider why periosteal grafts work for osteochondral defects, or why marrow stimulation techniques (microfracture, drilling) recruit MSCs to a cartilage defect, this paper is the mechanistic basis for both strategies.
Type X collagen expression by hypertrophic chondrocytes marks the terminal, irreversible step of the chondrogenic lineage — this is why growth plate hypertrophic zone pathology in skeletal dysplasias cannot be reversed, and it is a testable board fact.
One practical caveat: the International Society for Cellular Therapy recommends 'multipotent mesenchymal stromal cells' as the preferred designation, because single-cell multipotency in vivo remains unproven. Interpret MSC clinical trial results with that nuance in mind.
Caplan's 1991 paper formally names mesenchymal stem cells (MSCs) and answers the question: what cell gives rise to skeletal tissues, and what controls its fate? It synthesizes over 20 years of lineage work to show that bone and cartilage arise from a common progenitor through discrete, irreversible steps governed by genomic programming and local environmental cues. The paper then proposes that MSCs can be harvested, expanded ex vivo, and redeployed autologously — the conceptual origin of modern cell-based orthopedic therapies.
The vascular rule Caplan described explains observations residents encounter daily: periosteal stripping impairs fracture healing, avascular cartilage cannot spontaneously remodel into bone, and scaffold design for cartilage repair must exclude vasculature while bone scaffolds must invite it.
When you consider why periosteal grafts work for osteochondral defects, or why marrow stimulation techniques (microfracture, drilling) recruit MSCs to a cartilage defect, this paper is the mechanistic basis for both strategies.
Type X collagen expression by hypertrophic chondrocytes marks the terminal, irreversible step of the chondrogenic lineage — this is why growth plate hypertrophic zone pathology in skeletal dysplasias cannot be reversed, and it is a testable board fact.
One practical caveat: the International Society for Cellular Therapy recommends 'multipotent mesenchymal stromal cells' as the preferred designation, because single-cell multipotency in vivo remains unproven. Interpret MSC clinical trial results with that nuance in mind.